Gregory Russotti Sells 5,000 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) Stock

Century Therapeutics, Inc. (NASDAQ:IPSC) insider Gregory Russotti sold 5,000 shares of the business’s stock in a transaction dated Monday, April 22nd. The shares were sold at an average price of $3.10, for a total value of $15,500.00. Following the completion of the transaction, the insider now directly owns 297,319 shares in the company, valued at $921,688.90. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Century Therapeutics Price Performance

NASDAQ IPSC traded down $0.17 on Wednesday, hitting $2.96. 134,089 shares of the stock traded hands, compared to its average volume of 199,775. The business’s fifty day moving average is $4.13 and its two-hundred day moving average is $3.13. Century Therapeutics, Inc. has a 12 month low of $1.28 and a 12 month high of $5.51.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.07. Century Therapeutics had a negative return on equity of 54.73% and a negative net margin of 6,115.12%. The firm had revenue of $0.27 million during the quarter, compared to analyst estimates of $1.69 million. Analysts anticipate that Century Therapeutics, Inc. will post -1.94 earnings per share for the current year.

Institutional Investors Weigh In On Century Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Federated Hermes Inc. raised its position in Century Therapeutics by 0.4% during the fourth quarter. Federated Hermes Inc. now owns 618,482 shares of the company’s stock valued at $2,053,000 after purchasing an additional 2,500 shares in the last quarter. Abel Hall LLC purchased a new stake in Century Therapeutics during the fourth quarter valued at about $33,000. Finally, Avidity Partners Management LP raised its position in Century Therapeutics by 23.4% during the fourth quarter. Avidity Partners Management LP now owns 1,355,000 shares of the company’s stock valued at $4,499,000 after purchasing an additional 256,500 shares in the last quarter. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on IPSC. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Century Therapeutics in a research note on Friday, March 15th. Piper Sandler reaffirmed an “overweight” rating and issued a $9.00 target price (down from $10.00) on shares of Century Therapeutics in a report on Friday, April 12th. Finally, Canaccord Genuity Group upped their target price on Century Therapeutics from $22.00 to $24.00 and gave the company a “buy” rating in a report on Friday, March 15th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Century Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.60.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.